Bayer AG es una compañía de ciencias de la vida. Los segmentos de la compañía son productos farmacéuticos, salud del consumidor, ciencias de la cosecha, salud animal y Covestro.
El segmento de productos farmacéuticos se dedica al desarrollo de productos farmacéuticos recetados; anticonceptivos y productos médicos, como sistemas de inyección y agentes de contraste para procedimientos de diagnóstico.
El segmento de Salud del Consumidor se dedica al desarrollo de medicamentos de venta libre, productos dermatológicos y suplementos nutricionales.
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with colorectal cancerCombination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer / Companies plan indication-seeking trialmehr ...
Rivaroxaban demonstrates strong efficacy and safety profile in phase III study in children with thromboembolismPhase III EINSTEIN-Jr. study in children concludes the largest pediatric thromboembolism program delivering results consistent with those in adults / Study shows a low risk of recurrent venous thromboembolism (VTE) in children treated with rivaroxaban compared with standard of care with […]
Century Therapeutics launches with USD 250M financing for induced pluripotent stem cells (iPSC) allogeneic cell therapy platformCreated by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies / Leaps by Bayer leads investment round with USD 215 million commitment to develop next-generation immune oncology treatmentsmehr ...
Regorafenib to be tested in brain cancer patients in multi-arm cooperation trialGBM AGILE, an international platform trial sponsored by the Global Coalition for Adaptive Research (GCAR) to evaluate multiple therapies for patients with newly diagnosed and recurrent glioblastoma, is now open for enrollment in the US with regorafenib as the first treatment arm / Results […]
New data on larotrectinib efficacy in patients with TRK fusion cancer and primary CNS tumors or brain metastases presented at ASCO 2019In five TRK fusion cancer patients with brain metastases across different tumor histologies, the overall response rate was 60%, with disease control achieved in all patients / In 14 adult and pediatric patients with […]
Bayer's darolutamide plus androgen deprivation therapy (ADT) delays worsening of disease-related symptoms and maintains quality of life beyond end of study treatment compared to placebo plus ADT in men with non-metastatic castration-resistant prostate canResults of a new post-hoc analysis showed that treatment with darolutamide plus androgen deprivation therapy (ADT) delayed worsening of urinary and bowel […]
New data for larotrectinib show overall response rates of 94% in children and 76% in adults with TRK fusion cancer; clinical benefit demonstrated in patients with primary central nervous system tumors and brain metastasesIn children with TRK fusion cancer (n=34), the overall response rate (ORR) was 94% and durable, with median duration of response (DOR) […]